{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T10:40:07Z","timestamp":1744972807606,"version":"3.40.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","award":["This research was funded by F. Hoffmann-La Roche Ltd as part of Integrative Neuroscience Collaborations Network"],"award-info":[{"award-number":["This research was funded by F. Hoffmann-La Roche Ltd as part of Integrative Neuroscience Collaborations Network"]}],"id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s00415-025-13027-x","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T18:55:48Z","timestamp":1743879348000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recall vaccination increases detectable B-cell reactivity in persons with multiple sclerosis treated with ocrelizumab"],"prefix":"10.1007","volume":"272","author":[{"given":"Lucia","family":"Moiola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Mandelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej","family":"Tarkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annamaria","family":"Finardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianna","family":"Gabrieli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Zanetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorio","family":"Viti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Gattuso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosetta","family":"Pedotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erwan","family":"Muros-Le Rouzic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catarina","family":"Raposo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria A.","family":"Rocca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Bonini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7376-9425","authenticated-orcid":false,"given":"Roberto","family":"Furlan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agostino","family":"Riva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"key":"13027_CR1","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","volume":"27","author":"S Feng","year":"2021","unstructured":"Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, Dold C, Fuskova M, Gilbert SC, Hirsch I et al (2021) Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med 27:2032\u20132040. https:\/\/doi.org\/10.1038\/s41591-021-01540-1","journal-title":"Nat Med"},{"key":"13027_CR2","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s44197-023-00139-8","volume":"13","author":"S Porru","year":"2023","unstructured":"Porru S, Monaco MGL, Spiteri G, Carta A, Caliskan G, Viol\u00e1n C, Tor\u00e1n-Monserrat P, Vimercati L, Tafuri S, Boffetta P et al (2023) Incidence and determinants of symptomatic and asymptomatic SARS-CoV-2 breakthrough infections after booster dose in a large European multicentric cohort of health workers-ORCHESTRA project. J Epidemiol Glob Heal 13:577\u2013588. https:\/\/doi.org\/10.1007\/s44197-023-00139-8","journal-title":"J Epidemiol Glob Heal"},{"key":"13027_CR3","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1177\/13524585221102918","volume":"28","author":"I Schiavetti","year":"2022","unstructured":"Schiavetti I, Cordioli C, Stromillo ML, Ferr\u00f2 MT, Laroni A, Cocco E, Cola G, Pasquali L, Rilla MT, Signoriello E et al (2022) Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies. Mult Scler J 28:2106\u20132111. https:\/\/doi.org\/10.1177\/13524585221102918","journal-title":"Mult Scler J"},{"key":"13027_CR4","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/ana.26028","volume":"89","author":"MP Sormani","year":"2021","unstructured":"Sormani MP, Rossi ND, Schiavetti I, Carmisciano L, Cordioli C, Moiola L, Radaelli M, Immovilli P, Capobianco M, Trojano M et al (2021) Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol 89:780\u2013789. https:\/\/doi.org\/10.1002\/ana.26028","journal-title":"Ann Neurol"},{"key":"13027_CR5","doi-asserted-by":"publisher","first-page":"862","DOI":"10.3390\/pathogens12070862","volume":"12","author":"L Petrone","year":"2023","unstructured":"Petrone L, Sette A, de Vries RD, Goletti D (2023) The importance of measuring SARS-CoV-2-specific T-cell responses in an ongoing pandemic. Pathogens 12:862. https:\/\/doi.org\/10.3390\/pathogens12070862","journal-title":"Pathogens"},{"key":"13027_CR6","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1177\/13524585221102158","volume":"28","author":"G Guerrera","year":"2022","unstructured":"Guerrera G, Mandelli A, Finardi A, Orrico M, D\u2019Orso S, Picozza M, Noviello M, Beretta V, Bonetti B, Calabrese M et al (2022) Anti-SARS-CoV-2 T-stem cell memory persists in ocrelizumab-treated MS patients. Mult Scler J 28:1937\u20131943. https:\/\/doi.org\/10.1177\/13524585221102158","journal-title":"Mult Scler J"},{"key":"13027_CR7","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abl5344","author":"G Guerrera","year":"2021","unstructured":"Guerrera G, Picozza M, D\u2019Orso S, Placido R, Pirronello M, Verdiani A, Termine A, Fabrizio C, Giannessi F, Sambucci M et al (2021) BNT162b2 vaccination induces durable SARS-CoV-2 specific T cells with a stem cell memory phenotype. Sci Immunol. https:\/\/doi.org\/10.1126\/sciimmunol.abl5344","journal-title":"Sci Immunol"},{"key":"13027_CR8","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/ana.26343","volume":"91","author":"L Brill","year":"2022","unstructured":"Brill L, Raposo C, Rechtman A, Zveik O, Levin N, Oiknine-Djian E, Wolf DG, Vaknin-Dembinsky A (2022) Severe acute respiratory syndrome coronavirus 2 third vaccine immune response in multiple sclerosis patients treated with ocrelizumab. Ann Neurol 91:796\u2013800. https:\/\/doi.org\/10.1002\/ana.26343","journal-title":"Ann Neurol"},{"key":"13027_CR9","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1001\/jamaneurol.2021.3599","volume":"78","author":"L Brill","year":"2021","unstructured":"Brill L, Rechtman A, Zveik O, Haham N, Oiknine-Djian E, Wolf DG, Levin N, Raposo C, Vaknin-Dembinsky A (2021) Humoral and T-cell response to SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab. Jama Neurol 78:1510\u20131514. https:\/\/doi.org\/10.1001\/jamaneurol.2021.3599","journal-title":"Jama Neurol"},{"key":"13027_CR10","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.3390\/vaccines11091464","volume":"11","author":"C Woopen","year":"2023","unstructured":"Woopen C, Dunsche M, Rahbani GKA, Dillenseger A, Atta Y, Haase R, Raposo C, Pedotti R, Ziemssen T, Akg\u00fcn K (2023) Long-term immune response profiles to SARS-CoV-2 vaccination and infection in people with multiple sclerosis on anti-CD20 therapy. Vaccines 11:1464. https:\/\/doi.org\/10.3390\/vaccines11091464","journal-title":"Vaccines"},{"key":"13027_CR11","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200031","volume":"9","author":"C Woopen","year":"2022","unstructured":"Woopen C, Dunsche M, Haase R, Raposo C, Pedotti R, Akg\u00fcn K, Ziemssen T (2022) Timing of SARS-CoV-2 vaccination matters in people with multiple sclerosis on pulsed anti-CD20 treatment. Neurol Neuroimmunol Neuroinflamm 9:e200031. https:\/\/doi.org\/10.1212\/nxi.0000000000200031","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13027_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nprot.2006.1","volume":"1","author":"PK Chattopadhyay","year":"2006","unstructured":"Chattopadhyay PK, Yu J, Roederer M (2006) Live-cell assay to detect antigen-specific CD4+ T-cell responses by CD154 expression. Nat Protoc 1:1\u20136. https:\/\/doi.org\/10.1038\/nprot.2006.1","journal-title":"Nat Protoc"},{"key":"13027_CR13","doi-asserted-by":"publisher","first-page":"e192","DOI":"10.1016\/s1473-3099(20)30483-7","volume":"20","author":"JC Marshall","year":"2020","unstructured":"Marshall JC, Murthy S, Diaz J, Adhikari NK, Angus DC, Arabi YM, Baillie K, Bauer M, Berry S et al (2020) A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis 20:e192\u2013e197. https:\/\/doi.org\/10.1016\/s1473-3099(20)30483-7","journal-title":"Lancet Infect Dis"},{"key":"13027_CR14","doi-asserted-by":"publisher","first-page":"1032830","DOI":"10.3389\/fneur.2022.1032830","volume":"13","author":"KPJ van Dam","year":"2022","unstructured":"van Dam KPJ, Hogenboom L, Stalman EW, Kummer LYL, Steenhuis M, Keijser JBD, ten Brinke A, van Ham SM, Kuijpers TW, Rispens T et al (2022) Longitudinal SARS-CoV-2 humoral response in MS patients with and without SARS-CoV-2 infection prior to vaccination. Front Neurol 13:1032830. https:\/\/doi.org\/10.3389\/fneur.2022.1032830","journal-title":"Front Neurol"},{"key":"13027_CR15","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1002\/acn3.51664","volume":"9","author":"I Kister","year":"2022","unstructured":"Kister I, Curtin R, Pei J, Perdomo K, Bacon TE, Voloshyna I, Kim J, Tardio E, Velmurugu Y, Nyovanie S et al (2022) Hybrid and vaccine-induced immunity against SAR-CoV-2 in MS patients on different disease-modifying therapies. Ann Clin Transl Neurol 9:1643\u20131659. https:\/\/doi.org\/10.1002\/acn3.51664","journal-title":"Ann Clin Transl Neurol"},{"key":"13027_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.52081","author":"I Kister","year":"2024","unstructured":"Kister I, Curtin R, Piquet AL, Borko T, Pei J, Banbury BL, Bacon TE, Kim A, Tuen M, Velmurugu Y et al (2024) Longitudinal study of immunity to SARS-CoV2 in ocrelizumab-treated MS patients up to 2 years after COVID-19 vaccination. Ann Clin Transl Neurol. https:\/\/doi.org\/10.1002\/acn3.52081","journal-title":"Ann Clin Transl Neurol"},{"key":"13027_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103581","volume":"72","author":"MP Sormani","year":"2021","unstructured":"Sormani MP, Inglese M, Schiavetti I, Carmisciano L, Laroni A, Lapucci C, Rin GD, Serrati C, Gandoglia I, Tassinari T et al (2021) Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. EBioMedicine 72:103581. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103581","journal-title":"EBioMedicine"},{"key":"13027_CR18","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1111\/ene.15925","volume":"30","author":"C Louapre","year":"2023","unstructured":"Louapre C, Belin L, Marot S, Hippolyte A, Januel E, Ibrahim M, Jeantin L, Zafilaza K, Malet I, Charbonnier-Beaupel F et al (2023) Three to four mRNA COVID-19 vaccines in multiple sclerosis patients on immunosuppressive drugs: seroconversion and variant neutralization. Eur J Neurol 30:2781\u20132792. https:\/\/doi.org\/10.1111\/ene.15925","journal-title":"Eur J Neurol"},{"key":"13027_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104484","volume":"70","author":"JJ Sabatino","year":"2023","unstructured":"Sabatino JJ, Mittl K, Rowles W, Zamecnik CR, Loudermilk RP, Gerungan C, Spencer CM, Sagan SA, Alexander J, Mcpolin K et al (2023) Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators. Mult Scler Relat Disord 70:104484. https:\/\/doi.org\/10.1016\/j.msard.2022.104484","journal-title":"Mult Scler Relat Disord"},{"key":"13027_CR20","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200043","volume":"10","author":"G Disanto","year":"2023","unstructured":"Disanto G, Galante A, Cantu M, Sacco R, Mele F, Eisler JJ, Keller F, Bernasconi E, Sallusto F, Zecca C et al (2023) Longitudinal postvaccine SARS-CoV-2 immunoglobulin G titers, memory B-cell responses, and risk of COVID-19 in multiple sclerosis over 1 year. Neurol Neuroimmunol Neuroinflamm 10:e200043. https:\/\/doi.org\/10.1212\/nxi.0000000000200043","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13027_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.881988","volume":"13","author":"L Petrone","year":"2022","unstructured":"Petrone L, Tortorella C, Aiello A, Farroni C, Ruggieri S, Castilletti C, Meschi S, Cuzzi G, Vanini V, Palmieri F et al (2022) Humoral and cellular response to spike of delta SARS-CoV-2 variant in vaccinated patients with multiple sclerosis. Front Neurol 13:881988. https:\/\/doi.org\/10.3389\/fneur.2022.881988","journal-title":"Front Neurol"},{"key":"13027_CR22","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000013108.10.1212\/wnl.0000000000013108","author":"C Tortorella","year":"2021","unstructured":"Tortorella C, Aiello A, Gasperini C, Agrati C, Castilletti C, Ruggieri S, Meschi S, Matusali G, Colavita F, Farroni C et al (2021) Humoral- and T-cell\u2013specific immune responses to SARS-CoV-2 mRNA vaccination in patients with MS using different disease-modifying therapies. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000013108.10.1212\/wnl.0000000000013108","journal-title":"Neurology"},{"key":"13027_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01507-2","author":"SA Apostolidis","year":"2021","unstructured":"Apostolidis SA, Kakara M, Painter MM, Goel RR, Mathew D, Lenzi K, Rezk A, Patterson KR, Espinoza DA, Kadri JC et al (2021) Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med. https:\/\/doi.org\/10.1038\/s41591-021-01507-2","journal-title":"Nat Med"},{"key":"13027_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101351","volume":"5","author":"C Ulutekin","year":"2024","unstructured":"Ulutekin C, Galli E, Schreiner B, Khademi M, Callegari I, Piehl F, Sanderson N, Kirschenbaum D, Mundt S, Filippi M et al (2024) B cell depletion attenuates CD27 signaling of T helper cells in multiple sclerosis. Cell Rep Med 5:101351. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101351","journal-title":"Cell Rep Med"},{"key":"13027_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103729","volume":"60","author":"HM Bajwa","year":"2022","unstructured":"Bajwa HM, Novak F, Nilsson AC, Nielsen C, Holm DK, \u00d8stergaard K, Witt AH, Byg K-E, Johansen IS, Mittl K et al (2022) Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients. Mult Scler Relat Disord 60:103729. https:\/\/doi.org\/10.1016\/j.msard.2022.103729","journal-title":"Mult Scler Relat Disord"},{"key":"13027_CR26","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.3390\/vaccines9121470","volume":"9","author":"L Achtnichts","year":"2021","unstructured":"Achtnichts L, Jakopp B, Oberle M, Nedeltchev K, Fux CA, Sellner J, Findling O (2021) Humoral immune response after the third SARS-CoV-2 mRNA vaccination in CD20 depleted people with multiple sclerosis. Vaccines 9:1470. https:\/\/doi.org\/10.3390\/vaccines9121470","journal-title":"Vaccines"},{"key":"13027_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103776","volume":"61","author":"A Maglione","year":"2022","unstructured":"Maglione A, Morra M, Meroni R, Matta M, Clerico M, Rolla S (2022) Humoral response after the booster dose of anti-SARS-CoV-2 vaccine in multiple sclerosis patients treated with high-efficacy therapies. Mult Scler Relat Disord 61:103776. https:\/\/doi.org\/10.1016\/j.msard.2022.103776","journal-title":"Mult Scler Relat Disord"},{"key":"13027_CR28","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1111\/ene.15830","volume":"30","author":"I Schiavetti","year":"2023","unstructured":"Schiavetti I, Inglese M, Frau J, Signoriello E, Caleri F, Stromillo ML, Ferr\u00f2 MT, Rilla MT, Gandoglia I, Gazzola P et al (2023) Antibody response elicited by the SARS-CoV-2 vaccine booster in patients with multiple sclerosis: Who gains from it? Eur J Neurol 30:2357\u20132364. https:\/\/doi.org\/10.1111\/ene.15830","journal-title":"Eur J Neurol"},{"key":"13027_CR29","doi-asserted-by":"publisher","first-page":"1432348","DOI":"10.3389\/fimmu.2024.1432348","volume":"15","author":"F Novak","year":"2024","unstructured":"Novak F, Nilsson AC, Christensen EB, Stougaard CL, Barnkob MB, Holm DK, Witt AH, Byg K-E, Johansen IS, Nielsen C et al (2024) Humoral and cellular immune response from first to fourth SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients: a longitudinal cohort study. Front Immunol 15:1432348. https:\/\/doi.org\/10.3389\/fimmu.2024.1432348","journal-title":"Front Immunol"},{"key":"13027_CR30","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3390\/v15010230","volume":"15","author":"A Rak","year":"2023","unstructured":"Rak A, Gorbunov N, Kostevich V, Sokolov A, Prokopenko P, Rudenko L, Isakova-Sivak I (2023) Assessment of immunogenic and antigenic properties of recombinant nucleocapsid proteins of five SARS-CoV-2 variants in a mouse model. Viruses 15:230. https:\/\/doi.org\/10.3390\/v15010230","journal-title":"Viruses"},{"key":"13027_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/imr.13089","volume":"310","author":"A Sette","year":"2022","unstructured":"Sette A, Crotty S (2022) Immunological memory to SARS-CoV-2 infection and COVID-19 vaccines. Immunol Rev 310:27\u201346. https:\/\/doi.org\/10.1111\/imr.13089","journal-title":"Immunol Rev"},{"key":"13027_CR32","doi-asserted-by":"publisher","DOI":"10.22037\/aaem.v12i1.2357","volume":"13","author":"S SeyedAlinaghi","year":"2024","unstructured":"SeyedAlinaghi S, Pashapouryeganeh A, Dehghani S, Mirzapour P, Abbaspour F, Afroughi F, Rahimzadeh P, Najafi M, Ghasemi H, Mozafari N et al (2024) Feasibility and effectiveness of vaccines for COVID-19: an umbrella review. Arch Acad Emerg Med 13:e6. https:\/\/doi.org\/10.22037\/aaem.v12i1.2357","journal-title":"Arch Acad Emerg Med"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13027-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13027-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13027-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T10:10:00Z","timestamp":1744971000000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13027-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["13027"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13027-x","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"type":"print","value":"0340-5354"},{"type":"electronic","value":"1432-1459"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"4 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declared the following potential conflicts of interest with respect to the research, authorship, and\/or publication of this article: L.M., C.Z, F.E., M.A.R., M.L., R.F., and M.F. received honoraria as speaker or board member from Roche. R.P., E.M., and C.R. are employees of Hoffman-La Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The protocol and consent documents were approved by appropriate independent ethics committees at National Institute for Infectious Diseases \u201cLazzaro Spallanzani\u201d IRCCS.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standard statement"}},{"value":"All participants provided written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"314"}}